Capecitabine+Oxaliplatin

Phase 3Small molecule

Capecitabine+Oxaliplatin is one of 43 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Metastatic Colorectal CancerPreclinical

Active, not recruiting

Gastric CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Capecitabine and Oxaliplatin

FFudan University

Phase 3

2 2

Rivoceranib

EElevar Therapeutics

Phase 3

1 3

Capecitabine+Oxaliplatin

Roche

Phase 3

1 4

Gemzar

Johnson & Johnson

Preclinical

—5

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Completed·HHebei Medical University Fourth Hospital·Phase 2·NCT05086627·118 enrolled

Gastric Cancer1 trial

Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer

Completed·SSeoul National University Hospital·Phase 3·NCT02114359·111 enrolled

Metastatic Colorectal Cancer1 trial

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Completed· Roche logo

Roche··NCT01506167·719 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Capecitabine+Oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capecitabine+Oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capecitabine+Oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Capecitabine+Oxaliplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Locally-advanced Rectal Cancer1 trial

Gastric Cancer1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News